[Clinical course and effectiveness of combination chemotherapy for primary Hodgkin's disease involving lung and/or pleura].
A group of 87 patients with primary Hodgkin's disease involving the lungs and/or pleura was selected by means of radiological screening. Specific changes in the lungs and/or pleura appeared in the younger cohort 5.7 months (1-24 months) after first signs development, which presented mainly as nodular sclerosis. Such patients often revealed biological activity and intoxication symptoms (93% and 69%, respectively). X-ray examination detected lesions in tissues of the lung (35, 40%), pleura (34, 39%) and combinations of both (18, 21%); focal-infiltrative lung lesions - 32%, and exudative pleuritis - 31%. Combination chemotherapy (MOOP, ABVD, MOPP/ABV, BEACOPP) should be considered optimal in treating such patients, while the latter regimen is instrumental in dealing with unfavorable prognosis in order to crush drug resistance and improve end results.
Filatova
A V
AV
D000293:Adolescent; D000328:Adult; D000368:Aged; D024221:Antineoplastic Protocols; D014408:Biomarkers, Tumor / Q000032:analysis; D003131:Combined Modality Therapy; D005260:Female; D006689:Hodgkin Disease / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D008175:Lung Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D010997:Pleural Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy* / Q000473:pathology; D011859:Radiography; D016896:Treatment Outcome
D014408:Biomarkers, Tumor